TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSXV:ARCH.VN and OTC-BB:ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. David Luke as a Strategic Advisor for the clinical trial development of the Company’s drug candidates.
Read more at globenewswire.comArch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here